CHRONIC VIRAL HEPATITIS B;
EVALUATION OF LIVER FIBROSIS BY NONINVASIVE MARKER IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B
DOI:
https://doi.org/10.29309/TPMJ/2018.25.08.46Keywords:
Cirrhosis, Chronic Viral Hepatitis, Fibrosis, Hepatic Fibrosis and APRI, Viral Hepatitis, Hepatitis B, HbsAg, Liver FibrosisAbstract
Objectives: To determine the frequency of liver fibrosis by non invasive marker
in patients with chronic viral hepatitis B. Study Design: Cross sectional clearly investigate about
chronic viral hepatitis population. Setting: Liaquat University Hospital Hyderabad. Period: Six
months, 09-Jan-2014 to 08-July-2014. Patients and Methods: All the patients of 16-50 years of
age, of either gender with chronic viral hepatitis B infection for more than 6 months duration were
admitted and evaluated for liver fibrosis through non invasive marker (APRI). The SPSS was used
to manipulate the data. Results: During six month study period, total 140 patients with chronic
viral hepatitis B infected patients were evaluated for liver fibrosis. Majority of patients were from
urban areas 112/140 (80%). The mean ±SD for age of patients with chronic viral hepatitis B
infection was 37.95±9.77. The mean age ±SD of hepatic fibrotic patients was 35.72±7.62.
The mean ±SD for age of male and female population was 35.83±8.74 and 33.83 ± 6.53
respectively. The mean ± SD for APRI score in hepatic fibrotic subjects was 1.31±0.31 while in
relation to liver fibrotic male and female patients it was 0.91±0.21 and 1.00±0.32 respectively.
Majority of the subjects were 30-39 years of age and the male population predominant (p=0.02)
whereas the liver fibrosis was identified in 89/140 (63.5) [p=<0.01] as far as gender distribution
is concerned. Conclusion: APRI may be used as a simple and readily available tool for the
diagnosis of significant fibrosis in patients with chronic viral hepatitis B.